NDA 020329 · Pfizer
Glucotrol Xl
Glipizide · Oral · Sulfonylurea
Last checked: Nov 20, 2026Latest source record: Aug 3, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Apr 26, 1994
Approved uses
3
Original approval plus efficacy supplements
Registered trials
40
14 Phase 3, 1 recruiting
FAERS reports
61,002
34,236 serious, 5,360 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 21, 2026.
GLUCOTROL XL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. GLUCOTROL XL is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis 1.1 Limitations of Use GLUCOTROL XL is not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Mechanism: Glipizide primarily lowers blood glucose by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 1, 2002 Supplement 2 · Efficacy LabelLetter
- Feb 4, 1998 Supplement 1 · Efficacy
- Apr 26, 1994 Original approval · Type 3 - New Dosage Form
3 products under this application
- GLUCOTROL XL · GLIPIZIDE 2.5MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
- GLUCOTROL XL · GLIPIZIDE 5MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- GLUCOTROL XL · GLIPIZIDE 10MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Glipizide" as an intervention, any sponsor and status, largest first.
- Standard Medical Management in Secondary Prevention of Ischemic Stroke in ChinaPivotal-lookingCompleted
Peking Union Medical College HospitalAcademic, hospital or other
NCT00664846 · 4,000 participants (planned) · Start Apr 2008 · Primary completion Dec 2010
Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Asprin / Clopidogrel, Atorvastatin / Simvastatin · For: Stroke
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 46 sites in all
- Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00856284 · 2,639 participants · Start Mar 2009 · Primary completion Oct 2012
Drug: Alogliptin; Metformin and 1 more · For: Type 2 Diabetes Mellitus
Sites: Montgomery, Alabama; Muscle Shoals, Alabama; Pell City, Alabama · 261 sites in all
- Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes PatientsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00660907 · 1,217 participants · Start Mar 2008 · Primary completion Dec 2009
Drug: dapagliflozin; glipizide and 1 more · For: Type 2 Diabetes
Sites: Buenos Aires, Argentina; Caba, Argentina; Capital Federal, Argentina · 76 sites in all
- An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00094770 · 1,172 participants · Start Sep 2004 · Primary completion May 2006
Drug: sitagliptin (MK0431); Comparator: glipizide · For: Diabetes Mellitus, Type 2
- Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in HumansCompleted
Massachusetts General HospitalAcademic, hospital or other
NCT01762046 · 1,033 participants · Start Jan 2008 · Primary completion Dec 2015
Drug: Glipizide; Metformin · For: Diabetes Mellitus, Type 2
Sites: Boston, Massachusetts · 3 sites in all
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersAcademic, hospital or other
NCT06449235 · 938 participants (planned) · Start Sep 2024 · Primary completion Apr 2025
Drug: Omarigliptin; Sulphonylureas and 7 more · For: Type2diabetes
Sites: Dhaka, Bangladesh
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension PeriodPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00575588 · 891 participants · Start Dec 2007 · Primary completion Aug 2009
Drug: Metformin; Sulphonylurea and 1 more · For: Type 2 Diabetes
Sites: Hanko, Finland; Helsinki, Finland; Kuopio, Finland · 94 sites in all
- Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00086515 · 701 participants · Start Jun 30, 2004 · Primary completion Jul 20, 2005
Drug: Sitagliptin (MK0431); Placebo/Glipizide 5 mg and 2 more · For: Diabetes Mellitus, Type II
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased6,720
- nausea4,584
- drug ineffective3,585
- diarrhoea3,419
- fatigue3,075
- weight decreased2,839
- dizziness2,489
- dyspnoea2,463
- vomiting2,290
- blood glucose decreased2,246
- asthenia2,140
- pain2,126
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,259 |
| 2005 | 1,577 |
| 2006 | 2,728 |
| 2007 | 2,467 |
| 2008 | 2,046 |
| 2009 | 2,050 |
| 2010 | 2,348 |
| 2011 | 2,436 |
| 2012 | 2,470 |
| 2013 | 2,409 |
| 2014 | 2,696 |
| 2015 | 4,666 |
| 2016 | 4,388 |
| 2017 | 4,042 |
| 2018 | 4,166 |
| 2019 | 4,037 |
| 2020 | 3,225 |
| 2021 | 2,613 |
| 2022 | 2,209 |
| 2023 | 1,915 |
| 2024 | 1,925 |
| 2025 | 1,994 |
| 2026 | 1,336 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Glucotrol XL (Glipizide)
2024 spending
$52K
Beneficiaries
293
901 claims
Per beneficiary
$177
$0.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $845,441 |
| 2021 | $697,018 |
| 2022 | $157,698 |
| 2023 | $91,077 |
| 2024 | $51,977 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
· Lancet 1998 · Clinical Trial, Comparative Study
- Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS, Zheng YD, Yuan Y, et al. · Front Endocrinol (Lausanne) 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.
Volke V, Katus U, Johannson A, et al. · BMC Endocr Disord 2022 · Meta-Analysis, Systematic Review
- Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study.
Abdul-Ghani M, Puckett C, Abdelgani S, et al. · BMJ Open Diabetes Res Care 2025 · Clinical Trial, Phase IV, Comparative Study
- Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.
Domecq JP, Prutsky G, Leppin A, et al. · J Clin Endocrinol Metab 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis.
Andersen SE, Christensen M · Br J Clin Pharmacol 2016 · Systematic Review, Network Meta-Analysis
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.